Skip to Main Content

Rise and shine, everyone, another busy day is on the way. We can tell because the short person is up early and a parade of cars has floated by the Pharmalot campus. As for us, we are rummaging through emails and trying to decide what to do next. There is no shortage of options, though. To help us, we are brewing a cup of stimulation. Please feel free to join us. As always, here are some items of interest to help you on your own journey, such as it is. Hope all goes well and keep in touch. …

Marc Short, chief of staff to Vice President Mike Pence, owns between $506,043 and $1.64 million worth of individual stocks in companies doing work related to the pandemic response — holdings that could run afoul of conflict-of-interest laws, NPR reports. Many of the companies in which Short and his wife hold stock — including Abbott Labs (ABT), Gilead Sciences (GILD), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) — have been directly affected by or involved in the work of the Coronavirus Task Force, chaired by Pence.


Roche (RHHBY) and Gilead Sciences are initiating a late-stage trial of a two-drug combination in hopes of creating a new weapon in the battle against Covid-19, Bloomberg News writes. The study will pair Roche’s immune suppressor Actemra with Gilead’s antiviral remdesivir, the only drug shown so far to fight the coronavirus, in treating patients with severe pneumonia. The results of the combination will be compared to those from patients who receive remdesivir and a placebo.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!